Showing results (231-240 of 241) with videos related to
Sort By:
Pageof 25
Blood|September 26, 2007
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qAzra Raza, James A Reeves, Eric J Feldman, et al.Cell Stem Cell|February 21, 2017
Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable LeukemiaAndriana G Kotini, Chan-Jung Chang, Arthur Chow, et al.Nature Communications|February 23, 2016
MSI2 is required for maintaining activated myelodysplastic syndrome stem cellsJames Taggart, Tzu-Chieh Ho, Elianna Amin, et al.Journal of the National Comprehensive Cancer Network : JNCCN|January 2, 2017
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyPeter L Greenberg, Richard M Stone, Aref Al-Kali, et al.The Lancet. Oncology|August 4, 2015
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 studyFarhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.Leukemia|June 26, 2021
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasmsDavid P Steensma, Martin Wermke, Virginia M Klimek, et al.Blood|April 30, 2024
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromesMaria Sirenko, Elsa Bernard, Maria Creignou, et al.Blood|July 3, 2024
Molecular taxonomy of myelodysplastic syndromes and its clinical implicationsElsa Bernard, Robert P Hasserjian, Peter L Greenberg, et al.Nature Genetics|October 27, 2020
Cancer therapy shapes the fitness landscape of clonal hematopoiesisKelly L Bolton, Ryan N Ptashkin, Teng Gao, et al.NEJM Evidence|February 6, 2024
Molecular International Prognostic Scoring System for Myelodysplastic SyndromesElsa Bernard, Heinz Tuechler, Peter L Greenberg, et al.Pageof 25